FrancophonIA/ELRC3.0 huggingface dataset:
English: jaundice
Estonian: köha
English: Sabervel 150mg film-coated tablets are supplied in blister packs of 28, 56, 90 or 98 film- coated tablets.
Estonian: Sabervel 150 mg õhukese polümeerikilega kaetud tablette väljastatakse blisterpakendites 28, 56, 90 või 98 kaupa.
English: Musculoskeletal and connective tissue disorders: Common:
Estonian: leukotsütoklastiline vaskuliit Lihas-skeleti, sidekoe ja luude kahjustused: Sage:
English: Method of Administration
Estonian: Kasutamisviis
English: diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of ≤ 135/85 mmHg or a 10 mmHg reduction in systolic pressure if baseline was > 160 mmHg.
Estonian: Kõikide ravigruppide patsiendid said üldjuhul 2 kuni 4 antihüpertensiivset ravimit (nt diureetikumi, beetaadrenoblokaatorit, alfa-adrenoblokaaatorit), et saavutada ettenähtud vererõhu väärtus ≤ 135/85 mmHg või 10 mmHg süstoolse rõhu langus, kui algväärtus oli > 160 mmHg.
English: Very common:
Estonian: Uuringud: Väga sage:
English: White, concave, round, film-coated tablet with 7 mm diameter.
Estonian: Valge nõgus, ümmargune, õhukese polümeerikattega tablett, 7 mm läbimõõduga
English: White, concave, round, film-coated tablet with 11 mm diameter.
Estonian: Valge nõgus, ümmargune, õhukese polümeerikattega tablett, 11 mm läbimõõduga
English: What Sabervel looks like and contents of the pack Sabervel 150 mg film-coated tablets are white, concave, round, film-coated tablets with 9 mm diameter.
Estonian: Sabervel 150 mg õhukese polümeerikilega kaetud tabletid on valge nõgus, ümmargune, õhukese polümeerikattega tablett, 9 mm läbimõõduga
English: NAME OF THE MEDICINAL PRODUCT Sabervel 75 mg film-coated tablets irbesartan
Estonian: RAVIMPREPARAADI NIMETUS Sabervel 75 mg õhukese polümeerikilega kaetud tabletid irbesartaan
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of irbesartan Excipient with known effect:
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Üks õhukese polümeerikilega kaetud tablett sisaldab 75 mg irbesartaani.
English: White, concave, round, film-coated tablet with 9 mm diameter.
Estonian: Valge nõgus, ümmargune, õhukese polümeerikattega tablett, 9 mm läbimõõduga
English: Breast-feeding:
Estonian: Rasedus:
English: • to protect the kidney in patients with high blood pressure, type 2 diabetes and laboratory
Estonian: • neerude kaitsmiseks kõrgvererõhu, teist tüüpi suhkurtõve ja laboratoorselt tõestatud neerufunktsiooni kahjustusega haigetel.
English: NAME OF THE MEDICINAL PRODUCT Sabervel 300 mg film-coated tablets irbesartan
Estonian: RAVIMPREPARAADI NIMETUS Sabervel 300 mg õhukese polümeerikilega kaetud tabletid irbesartaan
English: Investigations:
Estonian: Imetamine:
English: (It is also better to avoid Sabervel in early pregnancy
Estonian: • kui rasedus on kestnud üle 3 kuu (ka raseduse algul on parem vältida Sabervel'i kasutamist - vt lõiku rasedus).
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 300 mg of irbesartan Excipient with known effect:
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Üks õhukese polümeerikilega kaetud tablett sisaldab 300 mg irbesartaani.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 150 mg of irbesartan Excipient with known effect:
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Üks õhukese polümeerikilega kaetud tablett sisaldab 150 mg irbesartaani.
English: NAME OF THE MEDICINAL PRODUCT Sabervel 150 mg film-coated tablets irbesartan
Estonian: RAVIMPREPARAADI NIMETUS Sabervel 150 mg õhukese polümeerikilega kaetud tabletid irbesartaan
English: 5.5 mEq/L) occurred in 29.4% of the patients in the irbesartan 300 mg group and 22% of the patients in the placebo group.
Estonian: Hüpertensiivsetest teise tüübi diabeediga mikroalbuminuuriaga ja normaalse neerufunktsiooniga patsientidest esines hüperkaleemiat (≥ 5,5 mEq/l) 29,4% (st väga sage) 300 mg irbesartaani saanutest ja 22% platseebogrupi patsientidest.
English: • Patients with high blood pressure and type 2 diabetes with kidney disease
Estonian: Hüpertensioon ja teist tüüpi diabeet koos neeruhaigusega
English: None of these increases were associated with identifiable clinical musculoskeletal events.
Estonian: Ükski nendest juhtumitest ei seostunud lihasskeleti
English: NAME OF THE MEDICINAL PRODUCT Sabervel 75 mg film-coated tablets
Estonian: RAVIMPREPARAADI NIMETUS Sabervel 75 mg õhukese polümeerikilega kaetud tabletid.
English: Renal impairment: in patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered.
Estonian: Neerupuudulikkus: irbesartaani farmakokineetika ei muutu märkimisväärselt neerupuudulikkusega või hemodialüüsitavatel patsientidel.
English: Suggested measures include induction of emesis and/or gastric lavage.
Estonian: Kutsuda esile oksendamine ja/või teha maoloputus, manustada aktiivsütt.
English: The frequency of the side effects listed below is defined using the following convention: Very common: at least 1 in 10 patients or more
Estonian: Väga sage: vähemalt ühel patsiendil kümnest või sagedamini.
English: Common: at least 1 in 100 and less than 1 in 10 patients Uncommon: at least 1 in 1000 and less than 1 in 100 patientsSide effects reported in clinical studies for patients treated with Irbesartan were:
Estonian: Aeg-ajalt: vähemalt ühel patsiendil 1000-st kuid harvem kui ühel l00-st.
English: Tablet core:
Estonian: Südame häired:
English: Hepatic impairment: in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.
Estonian: Maksapuudulikkus: irbesartaani farmakokineetika ei muutu märkimisväärselt kerge ja keskmise raskusega maksatsirroosiga patsientidel.
English: Renal and urinary disorders: Not known:
Estonian: Neeru ja kuseteede häired: Teadmata:
English: NAME OF THE MEDICINAL PRODUCT Sabervel 150 mg film-coated tablets
Estonian: RAVIMPREPARAADI NIMETUS Sabervel 150 mg õhukese polümeerikilega kaetud tabletid.
English: 40 mg of lactose monohydrate per film-coated tablet For the full list of excipients, see section 6.1.
Estonian: 40 mg laktoosmonohüdraati õhukese polümeerikilega kaetud tableti kohta.
English: NAME OF THE MEDICINAL PRODUCT Sabervel 300 mg film-coated tablets
Estonian: RAVIMPREPARAADI NIMETUS Sabervel 300 mg õhukese polümeerikilega kaetud tabletid.
English: • Patients with high blood pressure The usual dose is 150 mg once a day.
Estonian: Tavaline annus on 150 mg üks kord päevas.
English: 80 mg of lactose monohydrate per film-coated tablet For the full list of excipients, see section 6.1.
Estonian: 80 mg laktoosmonohüdraati õhukese polümeerikilega kaetud tableti kohta.
English: Each tablet contains 300 mg irbesartan
Estonian: TOIMEAINE(TE) SISALDUS Õhukese polümeerikilega kaetud tablett sisaldab 300 mg irbesartaani
English: 20 mg of lactose monohydrate per film-coated tablet For the full list of excipients, see section 6.1.
Estonian: 20 mg laktoosmonohüdraati õhukese polümeerikilega kaetud tableti kohta.
English: cough
Estonian: MUU
English: Each tablet contains 150 mg irbesartan
Estonian: TOIMEAINE(TE) SISALDUS Õhukese polümeerikilega kaetud tablett sisaldab 150 mg irbesartaani
English: 4 years
Estonian: 6.3 Kõlblikkusaeg 4 aastat.
English: Film-coating:
Estonian: Seedetrakti häired: Sage:
English: It contains the active substance filgrastim (30 or 48 million units).
Estonian: Ravim sisaldab toimeainena filgrastiimi (30 või 48 miljonit ühikut).
English: The full EPAR for Filgrastim Hexal can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Filgrastim Hexali kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Filgrastim Hexal is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Filgrastim Hexali võimalikult ohutu kasutamine.
English: The European Commission granted a marketing authorisation valid throughout the EU for Filgrastim Hexal on 06 February 2009.
Estonian: Euroopa Komisjon andis Filgrastim Hexali müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 6. veebruaril 2009.
English: The main measure in these studies was the neutrophil count over the first 10 days of treatment.
Estonian: Uuringute põhinäitaja oli neutrofiilide sisaldus ravi esimese 10 päeva jooksul.
English: What measures are being taken to ensure the safe and effective use of Filgrastim Hexal?
Estonian: Mis meetmed võetakse, et tagada Filgrastim Hexali ohutu ja efektiivne kasutamine?
English: Filgrastim Hexal is usually given in a specialised treatment centre, although patients who receive it by injection under the skin may inject themselves once they have been trained appropriately.
Estonian: Filgrastim Hexalit manustatakse tavaliselt spetsiaalses ravikeskuses, kuigi patsiendid, kellele seda manustatakse nahaaluse süstena, võivad pärast asjakohase väljaõppe saamist süstida end ise.
English: Four studies looked at the levels of neutrophils in the blood in a total of 146 healthy volunteers who received Filgrastim Hexal or Neupogen.
Estonian: Neljas uuringus vaadeldi neutrofiilide sisaldust veres kokku 146 tervel vabatahtlikul, kellele manustati kas Filgrastim Hexalit või Neupogeni.
English: Filgrastim Hexal filgrastim
Estonian: FILGRASTIM Hexal filgrastiim
English: This means that Filgrastim Hexal is similar to a biological medicine that is already authorised in the European Union (EU) and contains the same active substance (also known as the ‘reference medicine').
Estonian: See tähendab, et Filgrastim Hexal on sarnane bioloogilise ravimiga (võrdlusravimiga), millel juba on Euroopa Liidus müügiluba ning mis sisaldab sama toimeainet.
English: The Committee recommended that Filgrastim Hexal be given marketing authorisation.
Estonian: Komitee soovitas anda Filgrastim Hexali müügiloa.
English: For more information about treatment with Filgrastim Hexal, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Filgrastim Hexaliga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The CHMP decided that, in accordance with EU requirements, Filgrastim Hexal has been shown to have a comparable quality, safety and efficacy profile to Neupogen.
Estonian: Inimravimite komitee otsustas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Filgrastim Hexal võrdväärne kvaliteet ning ohutus- ja efektiivsusprofiil ravimiga Neupogen.
English: The active substance in Filgrastim Hexal, filgrastim, is very similar to a human protein called granulocyte colony stimulating factor (G CSF).
Estonian: Filgrastim Hexali toimeaine filgrastiim on väga sarnane inimvalguga, mida nimetatakse granülotsüütide kolooniat stimuleerivaks faktoriks (G-CSF).
English: Filgrastim Hexal can also be used in people who are about to donate blood stem cells for transplant, to help release these cells from the bone marrow.
Estonian: Lisaks võib Filgrastim Hexalit kasutada patsientidel, kes hakkavad loovutama siirdamiseks vere tüvirakke, et aidata nendel rakkudel luuüdist vabaneda.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Filgrastim Hexal.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The most common side effect with Filgrastim Hexal (seen in more than 1 patient in 10) is musculoskeletal pain (pain in the muscles and bones).
Estonian: Filgrastim Hexali kõige sagedam kõrvalnäht (esinenud enam kui 1 patsiendil 10st) on luu-lihaskonna valu.
English: Filgrastim Hexal was studied to show that it is comparable to the reference medicine, Neupogen.
Estonian: Filgrastim Hexalit uuriti, et näidata selle võrreldavust võrdlusravimiga Neupogen.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Filgrastim Hexal, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Filgrastim Hexali ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: The studies looked at the effects of single and repeated administration of various doses of the medicines, either injected under the skin or infused into a vein.
Estonian: Uuringutes vaadeldi eri ravimiannuste toimet ühekordsel ja korduval manustamisel.
English: This was considered sufficient to demonstrate that the benefits of Filgrastim Hexal are comparable to those of the reference medicine.
Estonian: Seda peeti piisavaks, et näidata Filgrastim Hexali ja selle võrdlusravimi kasulikkuse võrreldavust.
English: The replacement acts in the same way as naturally produced G CSF by encouraging the bone marrow to produce more white blood cells.
Estonian: Tehislik G-CSF toimib samal viisil kui looduslikult tekkiv G-CSF, soodustades leukotsüütide teket luuüdis.
English: Filgrastim Hexal and Neupogen brought about similar increases in blood neutrophil counts in healthy volunteers over the course of the studies.
Estonian: Uuringutes suurendasid Filgrastim Hexal ja Neupogen neutrofiilide sisaldust tervete vabatahtlike veres sarnasel määral.
English: Other information about Filgrastim Hexal
Estonian: Muu teave Filgrastim Hexali kohta
English: Filgrastim Hexal is used to stimulate the production of white blood cells in the following situations:
Estonian: Filgrastim Hexalit kasutatakse leukotsüütide (vere valgeliblede) tekke stimuleerimiseks järgmistel näidustustel:
English: This is a summary of the European public assessment report (EPAR) for Filgrastim Hexal.
Estonian: See on ravimi Filgrastim Hexal Euroopa avaliku hindamisaruande kokkuvõte.
English: infection, to reduce the risk of bacterial infections when other treatments are not appropriate.
Estonian: • püsiva neutropeenia raviks inimese immuunpuudulikkuse viiruse (HIV) kaugelearenenud nakkusega patsientidel bakteriaalsete infektsioonide riski vähendamiseks, kui muu ravi ei sobi.
English: What is the risk associated with Filgrastim Hexal?
Estonian: Mis riskid Filgrastim Hexaliga kaasnevad?
English: Filgrastim Hexal is a ‘biosimilar' medicine.
Estonian: Filgrastim Hexal on bioloogiliselt sarnane ravim.
English: For the full list of all side effects and restrictions, see the package leaflet.
Estonian: Filgrastim Hexali kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Filgrastim Hexal is a solution for injection or infusion (drip into a vein) in a pre-filled syringe.
Estonian: Filgrastim Hexal on süstelahus või infusioonilahus (veeni tilgutatav lahus) eeltäidetud süstlas.
English: What is Filgrastim Hexal?
Estonian: Mis on Filgrastim Hexal?
English: How has Filgrastim Hexal been studied?
Estonian: Kuidas Filgrastim Hexalit uuriti?
English: Why has Filgrastim Hexal been approved?
Estonian: Miks Filgrastim Hexal heaks kiideti?
English: Filgrastim Hexal is given by injection under the skin or infusion into a vein.
Estonian: Filgrastim Hexalit manustatakse nahaaluse süstega või veeniinfusiooniga.
English: How is Filgrastim Hexal used?
Estonian: Kuidas Filgrastim Hexalit kasutatakse?
English: Other side effects may be seen in more than 1 patient in 10, depending on the condition that Filgrastim Hexal is being used for.
Estonian: Olenevalt Filgrastim Hexali kasutamise näidustusest võivad ka muud kõrvalnähud esineda enam kui 1 patsiendil 10st.
English: The reference medicine for Filgrastim Hexal is Neupogen.
Estonian: Filgrastim Hexali võrdlusravim on Neupogen.
English: What is Filgrastim Hexal used for?
Estonian: Milleks Filgrastim Hexalit kasutatakse?
English: What benefit has Filgrastim Hexal shown during the studies?
Estonian: Milles seisneb uuringute põhjal Filgrastim Hexali kasulikkus?
English: How does Filgrastim Hexal work?
Estonian: Kuidas Filgrastim Hexal toimib?
English: ONIVYDE pegylated liposomal
Estonian: ONIVYDE pegüleeritud liposomaalne
English: Content (concentration)
Estonian: Pakendi sisu (kontsentratsi oon)
English: 4.3 mg/ml Concentrate for solution for infusion
Estonian: 4.3 mg/ml
English: EMA/CHMP/149365/2011 EMEA/H/C/002356
Estonian: EMA/149365/2011 EMEA/H/C/002356
English: The recommended maintenance dose is 10 to 20 mg once a day.
Estonian: Soovitatav säilitusannus on 10-20 mg üks kord
English: usually starts to have an effect after four to six weeks.
Estonian: Ravimi toime ilmneb tavaliselt 4-6 nädala pärast.
English: It is available as tablets (white and round: 10 mg; dark beige and triangular: 20 mg).
Estonian: Seda turustatakse tablettidena (valged ja ümmargused: 10 mg; tumebeežid ja kolmnurksed: 20 mg).
English: The full EPAR for Leflunomide Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Leflunomide Teva kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Leflunomide Teva EMA/CHMP/149365/2011
Estonian: Leflunomide Teva EMA/149290/2011
English: Leflunomide Teva treatment starts with a ‘loading dose' of 100 mg once a day for three days, followed by a maintenance dose.
Estonian: Ravi Leflunomide Tevaga alustatakse küllastusannusega 100 mg üks kord ööpäevas kolme päeva jooksul ning seejärel kasutatakse säilitusannust.
English: Because Leflunomide Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Leflunomide Teva on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: This is a summary of the European public assessment report (EPAR) for Leflunomide Teva.
Estonian: Käesolev dokument on ravimi Leflunomide Teva Euroopa avaliku hindamisaruande kokkuvõte.
English: Other information about Leflunomide Teva
Estonian: Muu teave Leflunomide Teva kohta
English: The European Commission granted a marketing authorisation valid throughout the European Union for Leflunomide Teva to TEVA Pharma B.V. on 10 March 2011.
Estonian: Euroopa Komisjon andis Leflunomide Teva müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele TEVA Pharma B.V.
English: This means that Leflunomide Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Arava.
Estonian: See tähendab, et Leflunomide Teva on sarnane võrdlusravimiga Arava, millel juba on Euroopa Liidus müügiluba.
English: Therefore, the CHMP's view was that, as for Arava, the benefit outweighs the identified risk.
Estonian: Seetõttu leidis inimravimite komitee, et nagu ka Arava korral, ületab Leflunomide Teva kasulikkus sellega kaasnevad riskid.
English: The CHMP concluded that, in accordance with EU requirements, Leflunomide Teva has been shown to have comparable quality and to be bioequivalent to Arava.
Estonian: Inimravimite komitee otsustas, et vastavalt Euroopa Liidu nõuetele on tõendatud Leflunomide Teva võrdväärne kvaliteet ja bioekvivalentsus ravimiga Arava.
English: Leflunomide Teva is a medicine that contains the active substance leflunomide.
Estonian: Leflunomide Teva on ravim, mis sisaldab toimeainena leflunomiidi.
English: For more information about treatment with Leflunomide Teva, read the package leaflet (also part of the EPAR) or contact your
Estonian: Kui vajate Leflunomide Tevaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Why has Leflunomide Teva been approved?
Estonian: Miks Leflunomide Teva heaks kiideti?
English: The medicine
Estonian: Kokkuvõte üldsusele
English: Because Leflunomide Teva is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Arava.
Estonian: Et Leflunomide Teva on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati Leflunomide Teva bioekvivalentsust võrdlusravimiga Arava.
English: Leflunomide Teva is a ‘generic medicine'.
Estonian: Leflunomide Teva on geneeriline ravim.
English: The Committee recommended that Leflunomide Teva
Estonian: Komitee soovitas anda Leflunomide Teva müügiloa.
English: Leflunomide Teva is used to treat adults with active rheumatoid arthritis (an immune system disease
Estonian: Leflunomide Tevat kasutatakse aktiivse reumatoidartriidi (liigesepõletikku põhjustav immuunsüsteemi haigus) raviks täiskasvanutel.
English: The doctor should carry out blood tests to check the patient's liver, white blood cell counts and platelet counts before prescribing Leflunomide Teva, and regularly during treatment.
Estonian: Arst teeb enne Leflunomide Teva määramist ja ravi ajal regulaarselt vereanalüüse patsiendi maksatalitluse ning leukotsüütide (valgeliblede) ja trombotsüütide (vereliistakute) sisalduse kontrollimiseks.
English: How does Leflunomide Teva work?
Estonian: Kuidas Leflunomide Teva toimib?
English: The active substance in Leflunomide Teva, leflunomide, is an immunosuppressant.
Estonian: Leflunomide Teva toimeaine leflunomiid on immunosuppressant (immuunvastust vähendav aine).
English: Leflunomide Teva treatment should be started and supervised by a specialist who has experience in the treatment of rheumatoid arthritis.
Estonian: Ravi Leflunomide Tevaga peab alustama reumatoidartriidi ravis kogenud arst ning see peab toimuma tema järelevalve all.
English: How has Leflunomide Teva been studied?
Estonian: Kuidas Leflunomide Tevat uuriti?
English: What are the benefits and risks of Leflunomide Teva?
Estonian: Milles seisneb Leflunomide Teva kasulikkus ja mis riskid ravimiga kaasnevad?
English: The medicine can only be obtained with a prescription.
Estonian: Leflunomide Teva on retseptiravim.
English: It is therefore important that you know about these medicines too.
Estonian: Seetõttu on oluline, et te teaksite ka nendest ravimitest.
English: The following observations were made:
Estonian: Täheldati järgnevat:
English: Practical recommendations deriving from this study are displayed below.
Estonian: Allpool on esitatud sellest uuringust saadud praktilised soovitused.
English: Harmful for those suffering from alcoholism.
Estonian: See on kahjulik neile, kes põevad alkoholismi.
English: In the majority of these patients the bleeding may have had other causes.
Estonian: Enamusel neist patsientidest võis verejooks omada teisi põhjusi.
English: A total of 10% of patients had previously used enfuvirtide.
Estonian: Kokku 10% patsientidest oli eelnevalt kasutanud enfuvirtiidi.
English: * AIDS defining illness
Estonian: *AIDS'i määratlev haigus
English: Date of latest renewal: 19 June 2015
Estonian: Müügiloa viimase uuendamise kuupäev: 19. juuni 2015
English: These changes may be seen on an ECG (electrocardiogram).
Estonian: Neid muutusi võib tuvastada EKG-s (elektrokardiogrammis).
English: Date of first opening:
Estonian: Esmakordse avamise kuupäev:
English: Typically, such reactions have been observed within the first few weeks or months of initiation of CART.
Estonian: Tavaliselt on sellised reaktsioonid esinenud CART esimestel nädalatel või kuudel.
English: ECG evaluation
Estonian: EKG hindamine
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 25 October 2005
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 25. oktoober 2005
English: Currently available data are described in section 5.1 and 5.2 but no recommendation on a posology can be made.
Estonian: Käesolevalt olemasolevaid andmeid on kirjeldatud lõikudes 5.1 ja 5.2, kuid annustamise kohta ei saa anda mingeid soovitusi.
English: Median (Min - Max)
Estonian: Mediaan (Min - Max)